P1278: ACTIVATION OF THE NECROPTOSIS PATHWAY PLAYS A ROLE IN SYNERGISM WITH COMBINATION OF THE IAP ANTAGONIST, TOLINAPANT AND HYPOMETHYLATING AGENTS (HMA) IN IN VITRO MODELS OF T-CELL LYMPHOMA (TCL).

• J. S. Manavalan, MD,
• I. Pal, PhD,
• A. Pursley,
• G. Ward, PhD,
• T. Smyth, PhD,
• M. Sims, PhD,
• D. Feith, PhD,
• T. P. Loughran, Jr, MD,
• O. A. O’Connor, MD, PhD,
• E. Marchi, MD, PhD

Affiliations

J. S. Manavalan, MD

1 Medicine/Hematology/Oncology, University of Virginia, Charlottesville, United States of America

I. Pal, PhD

1 Medicine/Hematology/Oncology, University of Virginia, Charlottesville, United States of America

A. Pursley

1 Medicine/Hematology/Oncology, University of Virginia, Charlottesville, United States of America

G. Ward, PhD

2 Astex Pharmaceuticals, Cambridge, United Kingdom

T. Smyth, PhD

2 Astex Pharmaceuticals, Cambridge, United Kingdom

M. Sims, PhD

2 Astex Pharmaceuticals, Cambridge, United Kingdom

D. Feith, PhD

1 Medicine/Hematology/Oncology, University of Virginia, Charlottesville, United States of America

T. P. Loughran, Jr, MD

1 Medicine/Hematology/Oncology, University of Virginia, Charlottesville, United States of America

O. A. O’Connor, MD, PhD

1 Medicine/Hematology/Oncology, University of Virginia, Charlottesville, United States of America

E. Marchi, MD, PhD

1 Medicine/Hematology/Oncology, University of Virginia, Charlottesville, United States of America